Trump pushes fast-track reviews for psychedelic medicines
TL;DR
President Trump issued an executive order directing the FDA (and DEA) to fast-track reviews for psychedelic drugs and to establish a pathway for access to investigational psychedelics under FDA review, including granting priority review vouchers for three serotonin 2A agonists. Companies like Compass Pathways welcomed the move as a step toward faster, regulated access to psychedelic medicines for mental illness while maintaining scientific rigor.
Topics:nationpolitics#breakthrough-therapy-designation#compass-pathways#executive-order#fda#politics#psychedelics
- Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster Fierce Biotech
- How Trump's psychedelics executive order could unlock stalled cannabis reform CNBC
- President Trump’s Landmark Order Advances Breakthrough Mental Health Treatments — Delivering New Hope to Veterans The White House (.gov)
- Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs The New York Times
- Psychedelic drug developers rally after Trump orders FDA to expedite reviews Reuters
Want the full story? Read the original reporting
Read on Fierce Biotech